Stephen K. Brannan - Mar 1, 2022 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role
Chief Medical Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Stock symbol
KRTX
Transactions as of
Mar 1, 2022
Transactions value $
-$745,110
Form type
4
Date filed
3/2/2022, 04:52 PM
Previous filing
Feb 17, 2022
Next filing
Apr 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $13.6K +2.5K +25% $5.45* 12.5K Mar 1, 2022 Direct
transaction KRTX Common Stock Options Exercise $71.1K +7.73K +61.82% $9.20* 20.2K Mar 1, 2022 Direct
transaction KRTX Common Stock Sale -$830K -7.73K -38.2% $107.38 12.5K Mar 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -2.5K -6.07% $0.00 38.7K Mar 1, 2022 Common Stock 2.5K $5.45 Direct F2
transaction KRTX Option (right to buy) Options Exercise $0 -7.73K -11.41% $0.00 60K Mar 1, 2022 Common Stock 7.73K $9.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2021.
F2 This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
F3 This option vests as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of March 21, 2019.